ABSTRACT
Pharma and clinical scientists are taking samples from clinical trials and retrospectively applying single-cell DNA technology with the Tapestri Platform to better understand the mutations underlying therapy resistance, relapse and remission. The ability to detect co-occurring mutations from the same single-cells allows researchers to reconstruct clonal architecture and phylogeny. Join us for Part 2 of Mission Bio's Publication Roundup in which we highlight several papers that have been applied to clinical trial samples.
